Keon Wook Kang

Dr. Keon Wook Kang


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
SJSung Baek Jeong
Sung Baek Jeong
JIJi Hye Im
Ji Hye Im
JYJeong-Hoon Yoon
Jeong-Hoon Yoon
QBQuyen Thu Bui
Quyen Thu Bui
SLSung Chul Lim
Sung Chul Lim
KKKeon Wook Kang
Keon Wook Kang
The most common therapy for estrogen receptor–positive breast cancer is antihormone therapy, such as tamoxifen. However, acquisition of resistance to tamoxifen in one third of patients presents a serious clinical problem. Polo-like kinase 1 (Plk1) is a key oncogenic regulator of completion of G2–M phase of the cell cycle. We assessed Plk1 expression in five chemoresistant cancer cell types and found that Plk1 and its downstream phosphatase Cdc25c were selectively overexpressed in tamoxifen-resistant MCF-7 (TAMR-MCF-7) breast cancer cells. Real-time monitoring of cell proliferation also showed that TAMR-MCF-7 cells were more sensitive to inhibition of cell proliferation by the ATP-competitive Plk1 inhibitor BI2536 than were the parent MCF-7 cells. Moreover, BI2536 suppressed expression of epithelial–mesenchymal transition marker proteins and 3D spheroid formation in TAMR-MCF-7 cells. Using TAMR-MCF-7 cell–implanted xenograft and spleen–liver metastasis models, we showed that BI2536 inhibited tumor growth and metastasis in vivo. Our results suggest that Plk1 could be a novel target for the treatment of tamoxifen-resistant breast cancer. Mol Cancer Ther; 17(4); 825–37. ©2018 AACR.

1 April 2017 in Cancer Letters
Verified
Journal Article
Closed access
QBQuyen Thu Bui
Quyen Thu Bui
JIJi Hye Im
Ji Hye Im
SJSung Baek Jeong
Sung Baek Jeong
YKYoung-Mi Kim
Young-Mi Kim
SLSung Chul Lim
Sung Chul Lim
KKKeon Wook Kang
Keon Wook Kang

18 July 2017 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
JYJin Won Yang
Jin Won Yang
HKHyo Seon Kim
Hyo Seon Kim
YCYong‐Won Choi
Yong‐Won Choi
YKYoung-Mi Kim
Young-Mi Kim
KKKeon Wook Kang
Keon Wook Kang

2 October 2023 in Experimental & Molecular Medicine
Verified
Journal Article
Open access
PDF file
YAYong Jin An
Yong Jin An
SJSihyang Jo
Sihyang Jo
JKJin-Mo Kim
Jin-Mo Kim
HKHan Sun Kim
Han Sun Kim
HKHyun Young Kim
Hyun Young Kim
SPSunghyouk Park
Sunghyouk Park
Histone acetylation involves the transfer of two-carbon units to the nucleus that are embedded in low-concentration metabolites. We found that lactate, a high-concentration metabolic byproduct, can be a major carbon source for histone acetylation through oxidation-dependent metabolism. Both in cells and in purified nuclei, 13C3-lactate carbons are incorporated into histone H4 (maximum incorporation: ~60%). In the purified nucleus, this process depends on nucleus-localized lactate dehydrogenase (LDHA), knockout (KO) of which abrogates incorporation. Heterologous expression of nucleus-localized LDHA reverses the KO effect. Lactate itself increases histone acetylation, whereas inhibition of LDHA reduces acetylation. In vitro and in vivo settings exhibit different lactate incorporation patterns, suggesting an influence on the microenvironment. Higher nuclear LDHA localization is observed in pancreatic cancer than in normal tissues, showing disease relevance. Overall, lactate and nuclear LDHA can be major structural and regulatory players in the metabolism–epigenetics axis controlled by the cell’s own status or the environmental status.

1 June 2014 in Journal of Hepatology
Verified
Journal Article
Closed access
JYJin Won Yang
Jin Won Yang
THTran Thi Hien
Tran Thi Hien
SLSung Chul Lim
Sung Chul Lim
DJDae Won Jun
Dae Won Jun
HCHong Seok Choi
Hong Seok Choi
KKKeon Wook Kang
Keon Wook Kang

1 September 2021 in Journal of Hepatology
Verified
Journal Article
Closed access
TYTaekyeong Yoo
Taekyeong Yoo
SJSae Kyung Joo
Sae Kyung Joo
HKHyo Jung Kim
Hyo Jung Kim
HKHyun Young Kim
Hyun Young Kim
HSHyungtai Sim
Hyungtai Sim
MCMurim Choi
Murim Choi